Patents by Inventor Antonio Lanzavecchia

Antonio Lanzavecchia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Human cytomegalovirus neutralizing antibodies and use thereof
    Patent number: 9803000
    Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: October 31, 2017
    Assignee: Institute of Research in Biomedicine
    Inventors: Antonio Lanzavecchia, Annalisa Macagno
  • Human cytomegalovirus neutralizing antibodies and use thereof
    Patent number: 9796772
    Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: October 24, 2017
    Assignee: Institute for Research in Biomedicine
    Inventors: Antonio Lanzavecchia, Annalisa MacAgno
  • Human cytomegalovirus neutralizing antibodies and use thereof
    Patent number: 9796771
    Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: October 24, 2017
    Assignee: Institute for Research in Biomedicine
    Inventors: Antonio Lanzavecchia, Annalisa Macagno
  • Human cytomegalovirus neutralizing antibodies and use thereof
    Patent number: 9725502
    Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.
    Type: Grant
    Filed: October 4, 2016
    Date of Patent: August 8, 2017
    Assignee: Institute for Research in Biomedicine
    Inventors: Antonio Lanzavecchia, Annalisa Macagno
  • NEUTRALIZING ANTI-INFLUENZA B ANTIBODIES AND USES THEREOF
    Publication number: 20170218054
    Abstract: The invention relates to antibodies and antigen binding fragments thereof that are capable of binding to influenza B virus hemagglutinin (HA) and neutralizing influenza B virus in two phylogenetically distinct lineages. In one embodiment, the antibody or antigen binding fragment is capable of binding to influenza B virus hemagglutinin and neutralizing influenza B virus in Yamagata and Victoria lineages.
    Type: Application
    Filed: July 14, 2015
    Publication date: August 3, 2017
    Inventors: Nicole Kallewaard-LeLay, Qing Zhu, Ebony Benjamin, Leslie Wachter, Andy Yuan, Josephine Mary McAuliffe, Davide Corti, Antonio Lanzavecchia
  • NEUTRALIZING ANTI-INFLUENZA A VIRUS ANTIBODIES AND USES THEREOF
    Publication number: 20170204167
    Abstract: The invention relates to antibodies, and antigen binding fragments thereof, that specifically bind to an epitope in the stem region of an influenza A hemagglutinin trimer and neutralize a group 1 subtype and a group 2 subtype of influenza A virus. The invention also relates to nucleic acids that encode, immortalized B cells and cultured single plasma cells that produce, and to epitopes that bind to such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, treatment and prevention of influenza A virus infection.
    Type: Application
    Filed: January 20, 2017
    Publication date: July 20, 2017
    Inventor: Antonio Lanzavecchia
  • HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF
    Publication number: 20170129939
    Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.
    Type: Application
    Filed: November 22, 2016
    Publication date: May 11, 2017
    Inventors: Antonio LANZAVECCHIA, Annalisa MACAGNO
  • HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF
    Publication number: 20170129940
    Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.
    Type: Application
    Filed: November 22, 2016
    Publication date: May 11, 2017
    Inventors: Antonio LANZAVECCHIA, Annalisa MACAGNO
  • HUMAN CYTOMEGALOVIRUS VACCINE COMPOSITIONS AND METHOD OF PRODUCING THE SAME
    Publication number: 20170119874
    Abstract: The present invention provides for a vector and a gene expression system for producing a soluble pentameric protein complex comprising the HCMV glycoproteins UL128, UL130, UL131, gH and gL or sequence variants thereof, as well as vaccine compositions comprising the same. The present invention further provides for a vaccine composition for use in prophylactically or therapeutically vaccinating against HCMV infections. Also disclosed are methods of producing the inventive vaccine. Furthermore, the present invention pertains to methods of vaccination of humans with the inventive vaccine composition.
    Type: Application
    Filed: April 23, 2015
    Publication date: May 4, 2017
    Inventors: Antonio Lanzavecchia, Laurent Perez
  • Human cytomegalovirus neutralising antibodies and use thereof
    Patent number: 9611316
    Abstract: The invention relates to neutralizing antibodies and antibody fragments having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for a combination of hCMV proteins UL130 and UL131A, or for a combination of hCMV proteins UL128, UL130 and UL131A. The invention relates also to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis and therapy of disease.
    Type: Grant
    Filed: November 11, 2015
    Date of Patent: April 4, 2017
    Assignee: Institute for Research in Biomedicine
    Inventors: Antonio Lanzavecchia, Annalisa Macagno
  • HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF
    Publication number: 20170081391
    Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.
    Type: Application
    Filed: October 4, 2016
    Publication date: March 23, 2017
    Inventors: Antonio LANZAVECCHIA, Annalisa MACAGNO
  • Neutralizing anti-influenza A virus antibodies and uses thereof
    Patent number: 9587010
    Abstract: The invention relates to antibodies, and antigen binding fragments thereof, that specifically bind to an epitope in the stem region of an influenza A hemagglutinin trimer and neutralize a group 1 subtype and a group 2 subtype of influenza A virus. The invention also relates to nucleic acids that encode, immortalized B cells and cultured single plasma cells that produce, and to epitopes that bind to such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, treatment and prevention of influenza A virus infection.
    Type: Grant
    Filed: July 18, 2011
    Date of Patent: March 7, 2017
    Assignee: THE INSTITUTE FOR RESEARCH IN BIOMEDICINE
    Inventor: Antonio Lanzavecchia
  • Human cytomegalovirus neutralizing antibodies and use thereof
    Patent number: 9527902
    Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: December 27, 2016
    Assignee: Institute for Research in Biomedicine
    Inventors: Antonio Lanzavecchia, Annalisa Macagno
  • Human cytomegalovirus neutralizing antibodies and use thereof
    Patent number: 9491906
    Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.
    Type: Grant
    Filed: May 17, 2016
    Date of Patent: November 15, 2016
    Assignee: Institute for Research in Biomedicine
    Inventors: Antonio Lanzavecchia, Annalisa Macagno
  • HUMAN CYTOMEGALOVIRUS NEUTRALISING ANTIBODIES AND USE THEREOF
    Publication number: 20160289302
    Abstract: The invention relates to neutralizing antibodies and antibody fragments having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for a combination of hCMV proteins UL130 and UL131A, or for a combination of hCMV proteins UL128, UL130 and UL131A. The invention relates also to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis and therapy of disease.
    Type: Application
    Filed: November 11, 2015
    Publication date: October 6, 2016
    Applicant: INSTITUTE FOR RESEARCH IN BIOMEDICINE
    Inventors: Antonio LANZAVECCHIA, Annalisa MACAGNO
  • HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF
    Publication number: 20160280769
    Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.
    Type: Application
    Filed: May 13, 2016
    Publication date: September 29, 2016
    Inventors: Antonio LANZAVECCHIA, Annalisa MACAGNO
  • HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF
    Publication number: 20160280770
    Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.
    Type: Application
    Filed: May 17, 2016
    Publication date: September 29, 2016
    Inventors: Antonio LANZAVECCHIA, Annalisa MACAGNO
  • NEUTRALIZING ANTI-INFLUENZA A ANTIBODIES AND USES THEREOF
    Publication number: 20160257732
    Abstract: The invention relates to antibodies and binding fragments thereof that are capable of binding to influenza A virus hemagglutinin and neutralizing at least one group 1 subtype and at least 1 group 2 subtype of influenza A virus. In one embodiment, an antibody or binding fragment according to the invention is capable of binding to and/or neutralizing one or more influenza A virus group 1 subtypes selected from H1, H2, H5, H6, H8, H9, H11, H12, H13, H16 and H17 and variants thereof and one or more influenza A virus group 2 subtype selected from H3, H4, H7, H1, 0, H14 and H15 and variants thereof.
    Type: Application
    Filed: October 1, 2014
    Publication date: September 8, 2016
    Inventors: Ebony Benjamin, Nicole Kallewaard-LeLay, Josephine Mary McAuliffe, Frances Palmer-Hill, Leslie Wachter, Andy Yuan, Qing Zhu, Davide Corti, Antonio Lanzavecchia, Barbara Guarino, Anna DeMarco
  • Human cytomegalovirus neutralizing antibodies and use thereof
    Patent number: 9371372
    Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: June 21, 2016
    Assignee: Institute for Research in Biomedicine
    Inventors: Antonio Lanzavecchia, Annalisa Macagno
  • Human cytomegalovirus neutralizing antibodies and use thereof
    Patent number: 9365636
    Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: June 14, 2016
    Assignee: Institute for Research in Biomedicine
    Inventors: Antonio Lanzavecchia, Annalisa Macagno